1004OFinal overall survival results of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) vs R-CHOP in transplantation-ineligible patients (pts) with newly diagnosed mantle-cell lymphoma (MCL): A randomized, open-label, phase III (LYM-3002) study
Saved in:
Published in | Annals of oncology Vol. 29; no. suppl_8 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford University Press
01.10.2018
|
Online Access | Get full text |
Cover
Loading…
ISSN: | 0923-7534 1569-8041 |
---|---|
DOI: | 10.1093/annonc/mdy286 |